Such a survival advantage was observed in monkey studies conducted by two teams of researchers, one led by Norman L. Letvin, M.D., of Beth Israel Deaconess Medical Center, Harvard Medical School and the NIAID Vaccine Research Center (VRC), and the other by Mario Roederer, Ph.D., of the VRC. The researchers found that monkeys vaccinated against simian immunodeficiency virus (SIV) -- a close relative of HIV that causes an AIDS-like disease in monkeys -- and then exposed to the virus survived significantly longer than unvaccinated animals exposed to SIV.
"The worldwide need for an HIV vaccine is profound," says Elias A. Zerhouni, M.D., director of the NIH. "In 2005, more than 11,000 people became infected with HIV every day. If that rate continues unchecked, the virus is going to infect another 40 million people during the coming decade."
"Although our ultimate goal is to have a vaccine that completely blocks HIV infection, this research suggests a potential benefit of even a partially effective vaccine," says NIAID Director Anthony S. Fauci, M.D.
Published in this week's issue of Science and this month's issue of the Journal of Experimental Medicine, the studies also identified a measurable marker of SIV vaccine effectiveness in monkeys -- something known as an immune correlate of vaccine efficacy. Further study is needed to determine if the immune correlate could predict the effectiveness of a vaccine against HIV in humans.
"Having an immune correlate of vaccine efficacy could markedly reduce the time it takes to evaluate whether a candidate HIV vaccine works in people,"
'"/>
Contact: Jason Socrates Bardi
jbardi@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
9-Jun-2006